OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75913JF635
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Block/Neutralize, Flow Cytometry
Label
Janelia Fluor 635
Antibody Source
Monoclonal Human IgG1 kappa Clone # R4930 (Oxelumab)
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Oxelumab binds to human OX40L, the ligand of OX40, stimulatory receptor that is expressed on activated T cells, natural killer (NK) cells and natural killer T (NKT) cells.
Specificity
Binds to human OX40L.
Clonality
Monoclonal
Host
Human
Isotype
IgG1 kappa
Applications for OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) [Janelia Fluor® 635]
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: OX40 Ligand/TNFSF4
Alternate Names
CD252, gp34, TNFSF4
Gene Symbol
TNFSF4
Additional OX40 Ligand/TNFSF4 Products
Product Specific Notices for OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...